Cendakimab治疗中重度特应性皮炎的随机临床试验
这项2期随机双盲安慰剂对照剂量探索试验纳入221例中重度特应性皮炎成人患者,评估皮下注射Cendakimab(选择性靶向IL-13)16周的疗效与安全性。各剂量组均显示进行性改善,总体安全耐受。
要点
- 720 mg每周一次组第16周EASI改善显著优于安慰剂,达到主要终点。
- 各剂量组因不良事件停药比例低,总体安全耐受。
核心结论
- Cendakimab在中重度特应性皮炎患者中有效、总体安全且耐受良好。
- 720 mg每周一次组第16周EASI评分较基线显著下降,达到主要终点。
- 16周治疗期间各剂量组均显示特应性皮炎进行性改善。
研究设计与样本
- 在5个国家69个中心入组对局部药物应答不佳的中重度特应性皮炎成人患者。
- 221例患者随机(1:1:1:1)接受Cendakimab 360 mg每2周、720 mg每2周、720 mg每周一次或安慰剂皮下注射。
主要发现
- 主要终点为基线至第16周EASI评分平均百分比变化。
- 因治疗中出现的不良事件导致停药者:720 mg每周一次组4例(7.4%)、720 mg每2周组2例(3.6%)、360 mg每2周组1例(1.8%)、安慰剂组2例(3.6%)。
关键数值与推荐
- EASI评分较基线平均百分比变化为主要疗效指标,采用层次检验并进行多重性校正。
- 检验顺序:先720 mg每周一次vs安慰剂,再720 mg每2周vs安慰剂,最后360 mg每2周vs安慰剂。
临床怎么用
- Cendakimab 720 mg每周一次皮下注射在中重度特应性皮炎16周治疗中显示显著EASI改善。
- 因层次检验中断,360 mg每2周与720 mg每2周的疗效结论需谨慎解读。
局限性
- 为2期剂量探索试验,样本量有限(221例随机)。
- 360 mg每2周组因层次检验序列中断未能声称统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cendakimab selectively targets interleukin (IL)-13, a type 2 cytokine implicated in atopic dermatitis (AD) pathogenesis, by inhibiting binding to its receptors (IL13R-α1 and IL13R-α2). Proof-of-concept work in AD supports using cendakimab for type 2 inflammatory diseases. OBJECTIVE: To evaluate the efficacy and safety of cendakimab compared with placebo in patients with moderate to severe AD. DESIGN, SETTING, AND PARTICIPANTS: This phase 2, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging clinical trial was conducted from May 2021 to November 2022. Adult patients with moderate to severe AD and inadequate response to topical medications were enrolled at 69 sites in 5 countries (US [n = 26], Japan [n = 17], Canada [n = 9], Poland [n = 9], and Czech Republic [n = 8]). Data were analyzed between April 25, 2023, and October 16, 2023. INTERVENTIONS: Patients were randomized (1:1:1:1) to receive subcutaneous cendakimab, 360 mg, every 2 weeks; 720 mg, every 2 weeks; 720 mg, once weekly; or placebo. MAIN OUTCOME AND MEASURE: Mean percentage change in Eczema Area and Severity Index scores from baseline to week 16. Hierarchical testing with multiplicity adjustment was performed for 720 mg, once weekly vs placebo, then 720 mg, every 2 weeks vs placebo, and then 360 mg, every 2 weeks vs placebo. RESULTS: Overall, 221 patients were randomized, and 220 received study drug (95 women [43%]; mean [SD] age, 37.7 [13.9] years; 720 mg, once weekly [54 (24%)]; 720 mg, every 2 weeks [55 (25%)]; 360 mg, every 2 weeks [55 (25%)]; placebo [56 (26%)]). The primary efficacy end point was met for cendakimab, 720 mg, once weekly vs placebo (-84.4 vs -62.7; P = .003) but missed statistical significance for 720 mg, every 2 weeks (-76.0 vs -62.7; P = .06). The treatment effect for 360 mg, every 2 weeks (-16.3; nominal P = .03 vs placebo) was comparable with 720 mg, once weekly (-21.8); however, significance was not claimed because the hierarchical testing sequence was interrupted. Of patients with treatment-emergent adverse events leading to discontinuation, 4 (7.4%) received 720 mg, once weekly; 2 (3.6%) 720 mg, every 2 weeks; 1 (1.8%) 360 mg, every 2 weeks; and 2 (3.6%) placebo. CONCLUSIONS AND RELEVANCE: The results of this randomized clinical trial indicated that cendakimab was effective, generally safe, and well-tolerated in patients with moderate to severe AD. The primary end point was met with a significant reduction in Eczema Area and Severity Index scores with 720 mg, once weekly at week 16. Cendakimab demonstrated progressive AD improvement at all doses during 16 weeks of treatment. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04800315.
引用
- Blauvelt A, Guttman-Yassky E, Lynde C, et al. Cendakimab in Patients With Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2024. PMID: 39018038. doi:10.1001/jamadermatol.2024.2131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。